Oct 27, 2020 / NTS GMT
Richard Soll - WuXi AppTec - Senior Advisor, Strategic Initiatives
Now the interview is part of our WuXi AppTec thought leadership series, Innovation That Matters. And we seek -- incept perspectives from key opinion leaders and industry executives such as yourself. Our series focuses on novel and newsworthy advances and bringing transformative medicines to patients, the impact of collaborations and partnerships, use of new technologies on the horizon, and final thoughts on the future outlook of our industry.
And it's a pleasure for me to introduce and interview you, Robert, as a co-founder of Galera and where you've served as Chief Operating Officer since 2015. The company is focused on aspects of radiotherapy treatment, looking at dismutase mimetics to reduce oral mucositis and also for increasing the efficacy of radiotherapy.
Questions and Answers:
Richard Soll - WuXi AppTec - Senior Advisor, Strategic InitiativesAnd so the first topic that I'd like to introduce to you is that, in today's world of cancer therapies, how does radiotherapy fit into
Trustpilot
